A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma

Trial Profile

A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 04 Apr 2018 According to a Nordic Nanovector media release, due to re-assessment in recruitment rate, company has to revised its timeline for this study. Company expects to dose first patient in 1H 2018 and expects results in 1H 2020 and first regulatory filing in 2020.
    • 27 Feb 2018 According to a Nordic Nanovector ASA media release, this trial was initiated in the fourth quarter of 2017.
    • 27 Feb 2018 According to a Nordic Nanovector ASA media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top